Investors

Company Overview

Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid and oncological diagnostics and therapeutics. AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through innovative pharmaceutical delivery systems, cannabinoid-based active pharmaceutical ingredients, and novel therapeutics.

The company’s subsidiary, Sapphire Biotech, Inc., is conducting research to understand the potential of its lead drug candidate, SPX-1009, to block the spread of tumor metastasis. Additionally, Sapphire’s proprietary diagnostic tool is being used to study the company’s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells. 

Investor Presentation

Email Alerts

Stay informed and receive company updates straight to your inbox

Recent News

AXIM® Biotechnologies Issues Update Letter to Shareholders

SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that it has issued a letter...

Latest Annual Filing

Fiscal Year Ended Dec 31, 2018